938440-64-3 | (5-(2-((2R,6S)-2,6-Dimethylmorpholino)-4-morpholinopyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$45.00	$31.00
5mg	98%	in stock	$78.00	$54.00
10mg	98%	in stock	$109.00	$76.00
50mg	98%	in stock	$510.00	$357.00
100mg	98%	in stock	$740.00	$518.00

Description

• Catalog Number: AH82397
• Chemical Name: (5-(2-((2R,6S)-2,6-Dimethylmorpholino)-4-morpholinopyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol
• CAS Number: 938440-64-3
• Molecular Formula: C25H31N5O4
• Molecular Weight: 465.5447399999999
• MDL Number: MFCD22666594
• SMILES: COc1ccc(cc1CO)c1ccc2c(n1)nc(nc2N1CCOCC1)N1C[C@H](C)O[C@@H](C1)C

Computed Properties

• Complexity: 643
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 34
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 5
• XLogP3: 2.6

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.

  Bioorganic & medicinal chemistry letters 20130301

• Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.

  Oncotarget 20120801

• Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.

  The Journal of biological chemistry 20120706

• Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin.

  Molecular cancer research : MCR 20120601

• The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.

  British journal of cancer 20120410

• Quantitative visualization of autophagy induction by mTOR inhibitors.

  Methods in molecular biology (Clifton, N.J.) 20120101

• Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.

  Methods in molecular biology (Clifton, N.J.) 20120101

• Mechanical regulation of glycogen synthase kinase 3β (GSK3β) in mesenchymal stem cells is dependent on Akt protein serine 473 phosphorylation via mTORC2 protein.

  The Journal of biological chemistry 20111111

• The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors.

  Biochemical and biophysical research communications 20110422

• Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.

  Journal of medicinal chemistry 20110310

• The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.

  Bioorganic & medicinal chemistry letters 20091015

• Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR).

  The Biochemical journal 20090701